Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ACHV
stocks logo

ACHV

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.274
-23.77%
--
--
-0.302
-18.24%
--
--
-0.315
-14.86%
Estimates Revision
The market is revising No Change the revenue expectations for Achieve Life Sciences, Inc. (ACHV) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 68.90%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+4.81%
In Past 3 Month
Stock Price
Go Up
up Image
+68.90%
In Past 3 Month
Wall Street analysts forecast ACHV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACHV is 14.60 USD with a low forecast of 10.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast ACHV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACHV is 14.60 USD with a low forecast of 10.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.780
sliders
Low
10.00
Averages
14.60
High
20.00
Current: 4.780
sliders
Low
10.00
Averages
14.60
High
20.00
JMP
Jason Butler
Outperform
initiated
$19
2025-11-25
Reason
JMP
Jason Butler
Price Target
$19
2025-11-25
initiated
Outperform
Reason
Citizens JMP analyst Jason Butler initiated coverage of Achieve Life Sciences with an Outperform rating and $19 price target. Achieve is developing cytisinicline, a nicotine dependence treatment for smoking cessation in adults, the analyst tells investors in a research note. The firm believes cytisinicline has a "highly differentiated" profile to Chantix and can both supplant and grow the current market.
H.C. Wainwright
Buy
initiated
$12
2025-08-21
Reason
H.C. Wainwright
Price Target
$12
2025-08-21
initiated
Buy
Reason
H.C. Wainwright initiated coverage of Achieve Life Sciences with a Buy rating and $12 price target. The firm believes the company's lead asset, cytisinicline oral tablet, has the potential to address a large unmet need in nicotine addiction treatment through a "differentiated" efficacy and tolerability profile.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Achieve Life Sciences Inc (ACHV.O) is -4.16, compared to its 5-year average forward P/E of -2.83. For a more detailed relative valuation and DCF analysis to assess Achieve Life Sciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.83
Current PE
-4.16
Overvalued PE
-1.78
Undervalued PE
-3.88

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.28
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.29
Undervalued EV/EBITDA
-0.86

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
193.95
Current PS
0.00
Overvalued PS
764.59
Undervalued PS
-376.70
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ACHV News & Events

Events Timeline

(ET)
2025-11-06
07:03:28
Achieve Life Sciences announces Q3 EPS of 28 cents, surpassing consensus estimate of 26 cents.
select
2025-11-03 (ET)
2025-11-03
08:40:10
Achieve Life Sciences Reports Key Milestones in ORCA-OL Trial
select
2025-10-20 (ET)
2025-10-20
08:41:01
Atkisson Named Chief Legal Officer at Achieve Life Sciences
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-26NASDAQ.COM
Citizens Begins Coverage of Achieve Life Sciences (ACHV) with a Positive Market Outlook

  • Analyst Coverage Initiation: Citizens initiated coverage of Achieve Life Sciences (NasdaqCM:ACHV) with a "Market Outperform" recommendation, projecting a 298.24% upside based on an average one-year price target of $15.81/share.

  • Institutional Ownership Trends: There are currently 136 funds reporting positions in Achieve Life Sciences, with a 5.56% decrease in the number of owners over the last quarter, while the average portfolio weight dedicated to ACHV increased by 10.81%.

  • Shareholder Activity: Propel Bio Management significantly reduced its holdings in ACHV by 62.50%, while other firms like SURI and FBDIX increased their allocations by 949.78% and 73.84%, respectively, indicating mixed sentiment among shareholders.

  • Market Sentiment Indicators: The put/call ratio for ACHV stands at 0.02, suggesting a bullish outlook, despite a 26.54% decrease in total shares owned by institutions over the past three months.

[object Object]
Preview
4.0
11-25Benzinga
Citizens Begins Coverage of Achieve Life Sciences with Market Outperform Rating and Sets Price Target at $19

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.

[object Object]
Preview
9.0
10-17Newsfilter
Achieve Life Sciences Awarded FDA Commissioner’s National Priority Voucher for Cytisinicline to Aid in E-cigarette and Vaping Addiction Treatment

  • FDA's Expedited Review for Cytisinicline: Achieve Life Sciences has received a Commissioner's National Priority Voucher from the FDA for cytisinicline, a potential first-in-class treatment for nicotine dependence specifically aimed at e-cigarette and vaping cessation, allowing for an expedited review process.

  • Clinical Efficacy and Future Trials: Cytisinicline has shown promising results in clinical trials, being 2.6 times more effective than placebo in helping users quit vaping, and the FDA has granted it Breakthrough Therapy designation, paving the way for further Phase 3 trials to support its approval.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Achieve Life Sciences Inc (ACHV) stock price today?

The current price of ACHV is 4.78 USD — it has decreased -2.05 % in the last trading day.

arrow icon

What is Achieve Life Sciences Inc (ACHV)'s business?

Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company. The Company focuses on addressing the global smoking health and nicotine dependence epidemic through the development and commercialization of cytisinicline. It has completed two Phase III studies with cytisinicline for smoking cessation and one Phase II study with cytisinicline in vaping cessation. Cytisinicline is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a dual-acting mechanism of action, being both a receptor agonist and antagonist. Cytisinicline is an investigational product candidate being developed for the treatment of nicotine dependence and has not been approved by the Food and Drug Administration for any indication in the United States. Cytisinicline acts as a partial agonist/antagonist, binding to alpha-4 beta-2 nicotinic receptors in the brain and is thought to have two potential consequences in treating nicotine dependence.

arrow icon

What is the price predicton of ACHV Stock?

Wall Street analysts forecast ACHV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACHV is 14.60 USD with a low forecast of 10.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Achieve Life Sciences Inc (ACHV)'s revenue for the last quarter?

Achieve Life Sciences Inc revenue for the last quarter amounts to -14.69M USD, increased 17.86 % YoY.

arrow icon

What is Achieve Life Sciences Inc (ACHV)'s earnings per share (EPS) for the last quarter?

Achieve Life Sciences Inc. EPS for the last quarter amounts to -11331000.00 USD, increased 9.25 % YoY.

arrow icon

What changes have occurred in the market's expectations for Achieve Life Sciences Inc (ACHV)'s fundamentals?

The market is revising No Change the revenue expectations for Achieve Life Sciences, Inc. (ACHV) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 68.90%.
arrow icon

How many employees does Achieve Life Sciences Inc (ACHV). have?

Achieve Life Sciences Inc (ACHV) has 25 emplpoyees as of December 05 2025.

arrow icon

What is Achieve Life Sciences Inc (ACHV) market cap?

Today ACHV has the market capitalization of 254.46M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free